| Catalog No. | HB185046 |
| Host species | Humanized |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | (scFv-heavy-kappa)-(scFv-heavy-lambda) |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact the lab for this information. |
| Expression system | Mammalian Cells |
| Accession | P20138 & P07766 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternative name | Bispecific, AMG-330, MT-114, 1679391-73-1 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Research Grade Eluvixtamab
Overview
Description
Eluvixtamab (HB185046) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation.
Highlights
- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Images
 SDS-PAGE |
SDS-PAGE for Research Grade Eluvixtamab |